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Abstract
Background: To assess radiobiological restrictions and tolerance doses as well as other toxic effects derived from 
repeated applications of single-fraction high dose rate irradiation of small liver volumes in clinical practice.
Methods: Twenty patients with liver metastases were treated repeatedly (2 - 4 times) at identical or intersecting 
locations by CT-guided interstitial brachytherapy with varying time intervals. Magnetic resonance imaging using the 
hepatocyte selective contrast media Gd-BOPTA was performed before and after treatment to determine the volume of 
hepatocyte function loss (called pseudolesion), and the last acquired MRI data set was merged with the dose 
distributions of all administered brachytherapies. We calculated the BED (biologically equivalent dose for a single dose 
d = 2 Gy) for different α/β values (2, 3, 10, 20, 100) based on the linear-quadratic model and estimated the tolerance 
dose for liver parenchyma D90 as the BED exposing 90% of the pseudolesion in MRI.
Results: The tolerance doses D90 after repeated brachytherapy sessions were found between 22 - 24 Gy and proved 
only slightly dependent on α/β in the clinically relevant range of α/β = 2 - 10 Gy. Variance analysis showed a significant 
dependency of D90 with respect to the intervals between the first irradiation and the MRI control (p < 0.05), and to the 
number of interventions. In addition, we observed a significant inverse correlation (p = 0.037) between D90 and the 
pseudolesion's volume. No symptoms of liver dysfunction or other toxic effects such as abscess formation occurred 
during the follow-up time, neither acute nor on the long-term.
Conclusions: Inactivation of liver parenchyma occurs at a BED of approx. 22 - 24 Gy corresponding to a single dose of 
~10 Gy (α/β ~ 5 Gy). This tolerance dose is consistent with the large potential to treat oligotopic and/or recurrent liver 
metastases by CT-guided HDR brachytherapy without radiation-induced liver disease (RILD). Repeated small volume 
irradiation may be applied safely within the limits of this study.
Background
Irradiation of liver malignancies has been shown benefi-
cial for patients with both primary and secondary intra-
hepatic tumors under specific oncological conditions, e.g.
oligotopic metastases. Both stereotactic irradiation and
image-guided brachytherapy have been described
recently with promising results [1-6].
A dose-response relationship exists with an association
between the delivery of a higher dose and improved clini-
cal outcome [7] but since the liver is a radiosensitive
organ there is an increasing risk of radiation-induced
liver disease (RILD) when the whole organ is exposed to
moderate doses, e.g. 30 Gy [8,9]. RILD, the most common
liver toxicity after radiation therapy, is a clinical syn-
drome of anicteric hepatomegaly, ascites, and elevated
liver enzymes occurring typically between 2 weeks to 3
months after completion of radiation therapy [10].
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For this reason, external total liver irradiation plays a
very limited role in the treatment of intrahepatic tumors.
However, treatment of parts of the liver with higher radi-
ation doses is possible without clinical consequences as
long as an adequate volume of normal liver is spared.
Hepatic toxicity due to radiation therapy has been
extensively investigated. Robertson et al. reported 12 of
26 patients with primary hepatobiliary cancers and mea-
surable treatment-related toxicity. Doses ranged from 36
Gy (whole liver) to 72.6 Gy (focal liver). Two patients
were diagnosed with nonfatal radiation hepatitis [11].
Cheng et al reported 12 out of 68 patients developing
RILD after three-dimensional conformal radiotherapy
(3D-CRT) of hepatocellular carcinoma with radiation
portals designed to include the gross hepatic tumor on
CT scan with 1.5-2 cm margins. No patient was given
radiation to the whole liver. The mean dose was 50.2 Gy
in daily fractions of 1.8-2 Gy [12]. Our own workgroup
has previously published 2 papers on human hepatic dose
tolerance after single small volume irradiation treatments
employing the brachytherapy model and hepatocyte
selective contrast agent to determine focal liver function
loss. Whereas the mean dose threshold for lasting focal
hepatic dysfunction was 15 Gy for all lesions. We found a
considerable dose volume effect up to a threshold of 18
Gy favouring very small irradiation volumes [13,14].
However, no human in vivo data on dose tolerance or late
toxic effects of repeated treatments of hepatic paren-
chyma is available today. The aim of the study described
herein was to determine hepatic threshold doses for
repeated small volume irradiation e.g. in case of tumor
recurrence after previous radiation treatment of liver
metastases, and to rule out the occurrence of any other
toxic effects.
Methods
General methodology
Patients eligible for this study had received at least 2
applications of computed tomography (CT)-guided
brachytherapy of adjacent liver areas with intersecting
dose distributions with time intervals of more than 4
weeks between radiation treatments. We sought to deter-
mine safety and clinical consequences of multiple appli-
cations of single-fraction irradiation of small liver
volumes. We utilized a methodology previously
described in a study on the tolerance dose of hepatic
parenchyma after singular single-fraction HDR irradia-
tion [13,14]. A fluoroscopy CT was used for catheter
positioning and 3D-CT data sets are acquired for dose
planning (Figure 1, 2). During follow-up to irradiation-
therapy, magnetic resonance imaging (MRI) with the
hepatocyte-directed contrast agent gadobenate dimeglu-
mine (Gd-BOPTA) was selected to identify the function
loss of liver parenchyma, hereinafter referred to as
"cumulative pseudolesion". Gadobenate dimeglumine is
an octadentate chelate of the paramagnetic ion gadolin-
ium. Its kinetic properties resemble those of conventional
iodinated contrast media and comprises a distribution
phase and an elimination phase [15]. Studies have shown
that this agent differs from other available gadolinium
chelates in selectively being taken up only by functioning
hepatocytes and excreted into the bile by the so-called
canalicular multispecific organic anion transporter
shared with bilirubin [15-17]. Changes in uptake of a
hepatocyte specific contrast media illuminate the final
path of the radiation injury, i.e. visualize areas of a dys-
functional hepatic system [18] (Figure 3). The histological
appearance of radiation induced liver damage indicates
that endothelial injury and subsequent obstruction of
centrilobular venules and sinusoids are the key events in
the pathogenesis of radiation injury of the liver. The path-
ological lesion resembles veno-occlusive disease [19-21]
(Figure 4).
After image fusion, the isodose lines calculated for
interstitial irradiation were projected onto the respective
MRI scans. In the study described herein, we employed
these techniques to assess the biologically equivalent tol-
erance dose of the irradiated volumes of liver paren-
chyma after repeated applications of single-fraction high-
dose rate (HDR) brachytherapy. The LQ-model, estab-
lished to predict late effects for different fractionation
schemes, was adopted for the HDR-brachytherapy
approach. The sensitivity of a tissue for a specific late
effect was described by the critical dose α/β in Gy.
Figure 1 Image-fusion: Contrast-enhanced computed tomogra-
phy (CT) after CT-guided positioning of brachytherapy catheters 
(arrows) in a liver metastasis of a colorectal carcinoma, merged 
with the last magnetic resonance imaging of the liver acquired 
after all interventions (grey delineation). The hypointensity area 
shows the impairment of hepatocyte function in the left liver lobe.Rühl et al. Radiation Oncology 2010, 5:44
http://www.ro-journal.com/content/5/1/44
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Study population
We retrospectively analyzed the dose distributions of
twenty patients. All patients received between two and
four applications of CT-guided HDR brachytherapy
either of the same liver lesion or in close proximity due to
local tumor recurrence or growth of a satellite lesion.
Written informed consent was obtained from all patients.
The patient population comprised of 10 men and 10
women; mean age was 64 years (51-84 years). Primary
malignancies were colorectal carcinoma (n = 18), cholan-
giocellular carcinoma (n = 1) and breast carcinoma (n =
1). Karnofsky performance score was higher than 80%.
Nineteen patients had received systemic anticancer treat-
ments before brachytherapy, terminated at least 4 weeks
Figure 2 Image fusion of CT-data set with the accumulated 3-D 
dosimetry of three different irradiation sessions. (a) Contrast-en-
hanced CT after first (No.1) CT-guided positioning of brachytherapy 
catheters (long arrow) in metastases of a colorectal carcinoma. The 
short arrow shows the 3-D dosimetry of another lesion, irradiated in 
session No.2. (b) Contrast-enhanced CT after third intervention (No.3) 
in the same patient. The arrow shows the upper boundary of the 3-D 
dosimetry of the lesion irradiated in session No.2. Physical doses are 
shown in the colour map.
Figure 3 Development of radiation injury of the liver after HDR 
brachytherapy: (a) Colorectal metastasis in liver segment IV (ar-
row), T1w-GRE 20 minutes after application of Gd-BOPTA. (b) Con-
trast-enhanced planning-CT and dosimetry after insertion of 
brachytherapy catheters (arrow) in the metastasis. The coloured lines 
indicate different isodoses. Applicated dose at the tumor margin was 
20 Gy. (c) MRI after 3 months with a decreased uptake (arrow) of Gd-
BOPTA around the irradiated and shrunken metastasis (T1w-GRE 20 
minutes after application of Gd-BOPTA).Rühl et al. Radiation Oncology 2010, 5:44
http://www.ro-journal.com/content/5/1/44
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before tumor ablation. Some of these drugs cause specific
toxic effects in the liver as steatosis and steatohepatis,
hyperbilirubinaemia and vascular changes, sinusoidal
obstruction or dilatation syndrome. Patients received in
particular irinotecan (n = 8), fluorouracil (n = 15),
capecitabine (n = 2), oxaliplatin (n = 5), epirubicine (n =
1) and gemcitabine (n = 1) before intervention. In
between the interventions and during postinterventional
surveillance 7 patients received again irinotecan, 5
patients received fluorouracil and oxaliplatine respec-
tively, capecitabine (n = 3), avastine (n = 2) and UFT (n =
1).
Treatment was carried out consecutively without selec-
tion or randomisation. There was a minimum interval of
4 weeks and a maximum of 14 months between sequen-
tial applications (table 1). The decision to treat or re-treat
any lesion was taken individually following oncological
considerations.
Only patients who underwent more than one applica-
tion of CT-guided HDR-brachytherapy with intersecting
dose distributions were included. Normal liver function
based on laboratory parameters as well as clinical exami-
nation was acquired before CT-guided brachytherapy.
We excluded patients with any clinical or laboratory
sign of liver function degradation before therapy.
Interventional technique and irradiation
The technique of CT-guided brachytherapy has been
described in detail elsewhere [22]. Positioning of the
brachytherapy applicators was performed with a fluoros-
copy CT (Siemens, Erlangen, Germany). After catheter
placement a spiral CT of the liver (slice thickness: 5 mm,
increment: 5 mm), enhanced by i.v. application of iodide
contrast media (100 mL Ultravist 370, flow: 1 mL/s; start
delay: 80s), was acquired using the breath-hold technique
for treatment planning purposes.
The HDR afterloading system (GammaMed, Varian,
Charlottesville,VA) used a 192Iridium source of 10Ci. The
source diameter was <1 mm and dwell positions were
located every 5 mm. Dwell times were corrected auto-
matically according to the actual source strength.
Treatment planning and dosimetry analysis
Treatment planning employed BrachyVision (Varian
Medical Systems, Palo Alto, CA). A radiation oncologist
and radiologist jointly performed the planning process,
i.e. delineation of the clinical target volume CTV (gross
t u m o r  v o l u m e  G TV  p l u s  s a f e t y  m a r g i n  o f  a  f e w  m m )
according to clinical considerations. The prescribed dose
to enclose the CTV ranged from 15 to 25 Gy (mean 20
Gy, average 18.27 Gy) (table 1). In organs at risk (intes-
tine, stomach) D1 ml was prescribed to be < 15 Gy. The
volume dose to the liver (D15 Gy, D10 Gy, D7 Gy) was kept as
small as reasonable.
All applications were performed as a single dose
employment.
Follow-Up
MRI examinations were performed in 20 patients 1 day
before, 3 days, 6 weeks and following every 12 weeks after
irradiation. The MRI protocol was comprised of the fol-
lowing sequences: T2-w breathing-triggered UTSE (TE/
TR 90/2,100 ms), T1-w breath-hold gradient echo (GRE)
(TE/TR 5/30 ms, flip angle 30°) precontrast, 20 s and 2 h
post i.v. application of 15 mL Gd-BOPTA (Multihance;
Bracco, Princeton, NJ). The slice thickness was 8 mm,
acquired in interleafed mode with no gap applied.
At the same control dates we also assessed the follow-
ing laboratory parameters: bilirubin, aspartate amin-
otransferase, alanine aminotransferase, alkaline
phosphatase, albumin, ammonia and C-reactive protein
to assess treatment-related toxicity using Radiation Ther-
apy Oncology Group (RTOG) toxicity score.
Image registration
All 3D-dosimetry data calculated by BrachyVision during
all CT-guided brachytherapies were merged with the last
MRI-data set which had been acquired during a period of
≤12 months after the last intervention. All data were pro-
cessed by anisoscalar image registration (Figure. 1, 2). By
reducing the images to contain liver parenchyma and a
small surrounding margin (approx. 1 cm), anisotropic
image fusion was sufficient to achieve accuracy better
than 5 mm for the liver surface and prominent anatomic
structures (e.g. large vessels) [14].
The registration routine of the algorithm was based on
normalized mutual information and has been described
by Studholme et al. [23]. We employed a modified inde-
Figure 4 Liver biopsy. Biopsy was performed to rule out a sus-
pected local recurrence. Tissue had been exposed to approximately 
20 Gy two months ago. Heterogenous congestion of the sinusoids 
with beginning atrophy of liver cells. Hematoxylin-eosin, original mag-
nification: ?100.R
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Table 1: The extent of the irradiation effects ("cumulative pseudolesion" in cm3) and calculated D90 (for α/β = 2 Gy) with respect to the minimal prescribed dose inside 
of the clinical target volume (CTV) in the different irradiation sessions.
Pat. D90 (2 Gy) Cum. Pseudo-le-
sion Volume 
(cm3)
Fractions (n) Interval between 
inter-ventions 
(months)
Interval between 
first irradiation & 
last MRI (months)
Interval between 
last irradiation & 
last MRI (months)
Minimal 
prescribed dose 
inside CTV (Gy)
Liver Volume 
(cm3)
1 18.80 289 3 3/3 17 11 20/20/20 1960
2 16.20 327 2 7 14 7 25/15 2184
3 35.20 135 4 7/1/8 31 3 15/20/20/20 1123
4 25.30 172 3 4/3 18 11 20/20/15 1548
5 17.20 710 2 12 5 4 15/15 2077
6 25.15 381 2 13 13 12 15/20 1357
7 16.40 239 2 7 18 11 25/15 1847
8 14.35 803 2 6 13 7 15/20 1463
9 31.90 92 4 4/4/8 24 7 15/15/20/20 1424
10 23.65 425 2 14 18 4 20/15 2054
11 28.35 178 2 5 10 4 15/20 1662
12 21.64 668 3 4/6 16 6 20/15/20 2165
13 21.70 207 2 10 12 3 15/15 1439
14 15.90 529 3 1/5 9 4 15/15/15 1441
15 16.30 238 2 11 14 3 20/15 2025R
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16 21.75 244 3 1/7 10 3 20/20/15 1604
17 33.20 476 4 1/10/1 19 9 25/15/25/25 1951
18 20.55 227 2 1 5 4 20/20 1387
19 14.90 319 2 11 10 8 15/15 1428
20 29.60 75 2 9 12 3 20/20 1246
Mean 22.40 336.7 3 5 14 6 20 1669.16
The different time intervals between the interventions and the different time intervals between the interventions and acquisition of MRI examinations are shown.
Table 1: The extent of the irradiation effects ("cumulative pseudolesion" in cm3) and calculated D90 (for α/β = 2 Gy) with respect to the minimal prescribed dose inside 
of the clinical target volume (CTV) in the different irradiation sessions. (Continued)Rühl et al. Radiation Oncology 2010, 5:44
http://www.ro-journal.com/content/5/1/44
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pendent implementation of this algorithm within the 3D
visualization software Amira version 3.1 (Mercury Com-
puter Systems, Inc, San Diego, USA). The accuracy of the
implemented algorithm was verified by Rohlfing et al.
[24].
Quantitative analysis
For every patient, we calculated the cumulative biologi-
cally equivalent dose BED in every voxel over the whole
liver for different α/β-values (2, 3, 10, 20, 100) by the fol-
lowing equation [25]:
where DK is the dose per voxel deposited during the
intervention k = 1,...,n and Dtot is the BED per voxel with
respect to conventional fractionation.
Every lesion was the result of repetitive single interven-
tions with different dose distributions. On the T1-w late
Gd-BOPTA enhanced images of the last MRI acquired
after the last therapy, two experienced GI-radiologists
evaluated the fused images of MRI and dose distributions
by delineating the border of hypointensity in the irradi-
ated liver area in consensus. In liver regions with no
detectable uptake of Gd-BOPTA (hypointensity) we
assumed radiation-induced damage of liver tissue [13,14].
Based on the total 3D D90-data set, Amira software cal-
culated the dose-volume histograms for a set of α/β val-
ues (2, 3, 10, 20, 100) (Figure 5) to determine the D90 (α/β)
for every cumulative pseudolesion, i.e. the BED exposing
90% of the pseudolesion in MRI.
Statistical analysis
Standard Pearson correlation coefficients were deter-
mined to perform an univariate correlation analysis with
following variables used: D90 (for α/β = 2), number of
interventions, interval between first irradiation and last
MRI, interval between last irradiation and last MRI,
mean interval between several interventions and volume
of the cumulative pseudolesion. Kendall's W-test for
related samples was used to test the difference with
respect to various α/β-values.
W e compared 2 groups of patients with pseudolesion
volumes of ≤200 mL (n = 5) or >200 mL (n = 15). The
comparison between the D90(2 Gy) of the two groups was
performed by using an unpaired t- test.
Analyses were performed using the Statistical Package
for the Social Sciences, version 13.0.0 (SPSS for Win-
dows, Chicago, Illinois, USA). A p-value < 0.05 was con-
sidered statistically significant.
Results
The volumes of radio-affected liver tissue (pseudolesion)
are presented in Table 1 in dependency on the time inter-
vals between the interventions and the time intervals
from interventions to MRI examinations. The lesion size
overall ranged from 75 cm3 to 803 cm3 (median 266.5
cm3), the whole liver volume ranged from 1123 cm3 to
2184 cm3 (median 1576 cm3). The time interval from the
first brachytherapy to the last MRI ranged from 5 to 31
months (median 13.5 months), and from the last
brachytherapy to the last MRI from 3 to 12 months
(median 5 months), respectively. The MRI-data we used
was the latest MRI acquired during a period of median 5
months after the last intervention.
Table 2 shows the calculated D90 covering the inacti-
vated liver tissue corresponding to variable α/β values.
The mean tolerance doses ranged from 22.40 Gy for α/β
= 2 to 23.34 Gy for α/β = 10, and 24.08 Gy for α/β = 20 to
26.17 Gy for α/β = 100, respectively. The differences in
the D90 were statistically significant, but the differences
for clinical relevant α/β-values between 2 and 10 were
smaller than 1 Gy (table 2, Figure 5, 6).
The D90 (for α/β = 2) and the interval between the first
irradiation and the last MRI correlated significantly (p =
0.005) as a result of ongoing repair or regeneration. A
correlation was also shown between the D90 and the num-
ber of interventions, likely as a result of better recovery in
case of a smaller number of irradiation treatments (p =
0.004) (table 3). There was a trend for a positive correla-
tion (p = 0.092) between D90  and the mean interval
between the whole series of several interventions. The
time interval between repeated interventions did increase
the D90(2 Gy), indicating that the time available for regener-
ation influenced the dose tolerance. Conversely, a signifi-
cant inverse relationship (p = 0,037) between the volume
of the pseudolesion and D90 was found (table 3).
After definition of three groups with different
pseudolesion volumes (1: up to 199 mL (30.1 Gy), 2: 200-
399 mL (19.1 Gy) and 3: ≥400 mL (21 Gy)), the Bonfer-
roni-test revealed a significant difference for the D90(2 Gy)
between group 1 and both other groups, while there was
no difference between group 2 and 3. However, there was
a cut off at 200 mL and the comparison of the two groups
regarding patients with different pseudolesion volumes
showed a difference between the D90(2 Gy) (30.1 Gy vs. 19.1
Gy) (p = 0.01) (table 4).
There was no significant correlation with all the other
variables tested: a) the interval from last irradiation to
MRI did not correlate with the D90(2 Gy) (p = 0.834); b) the
intervals between repeated irradiations and MRI did not
correlate with the mean interval between all interven-
DD D kk
k
tot
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b
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Table 2: The D90 for impairment of hepatocyte function ("cumulative pseudolesion") calculated for different α/β-values 
(2, 3, 10, 20, 100).
D90 (Gy) for impairment of hepatocyte function for different α/β-values
Patient α/β = 2 α/β = 3 α/β = 10 α/β = 20 α/β = 100
1 18.80 19.00 19.99 20.90 23.60
2 16.20 16.40 16.65 17.30 18.80
3 35.20 35.70 36.50 36.90 38.10
4 25.30 25.40 26.20 27.00 29.60
5 17.20 17.30 18.00 18.65 20.45
6 25.15 25.20 25.65 26.15 27.85
7 16.40 16.60 17.50 18.45 20.70
8 14.35 14.45 15.20 15.87 17.55
9 31.90 32.60 33.40 34.00 36.80
10 23.65 23.80 24.75 25.78 28.80
11 28.35 28.40 29.90 30.90 34.70
12 21.64 21.70 22.65 23.48 26.10
13 21.70 21.80 22.45 23.10 25.00
14 15.90 16.10 17.10 17.90 20.10
15 16.30 16.40 16.95 17.70 19.45
16 21.75 21.90 22.10 22.90 25.20
17 33.20 34.10 34.90 35.60 37.10
18 20.55 20.60 20.85 21.35 22.50
19 14.90 15.10 16.00 16.80 19.00
20 29.60 29.90 30.00 30.80 31.90
Mean 22.40 22.62 23.34 24.08 26.17
Stand. deviation 6.47 6.62 6.64 6.61 6.68Rühl et al. Radiation Oncology 2010, 5:44
http://www.ro-journal.com/content/5/1/44
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tions. Next to that, the number of interventions did not
negatively influence hepatocyte function recovery at spe-
cific dose levels.
All patients included in this study demonstrated nor-
mal liver function parameters before CT-guided
brachytherapy. There was no Grade 2 or above hemato-
logic toxicity according RTOG toxicity scale. No patient
developed symptoms of acute or late chronic liver dys-
function in between the interventions or during follow
up, which could be related to irradiation.
Discussion
The tolerance doses of the entire liver or large portions of
the liver to external irradiation have been described pre-
viously in the literature. A TD5/5 of 30 Gy is given for the
whole liver, while one-third to two-third of the liver toler-
ate higher doses of 35 Gy to 50 Gy, respectively [19,26].
Small volume effects have been described for both ste-
reotactic radiation as well as CT-guided brachytherapy
treatments [1,5,14]. Promising results with sustained
local control rates have been achieved.
Ricke et al. reported a median survival of 23.4 months
after image-guided high dose rate brachytherapy (mini-
mal tumor-enclosing doses of 15 Gy, 20 Gy, or 25 Gy as
D100) of seventy-three patients with 199 colorectal liver
metastases [5].
Lee et al. showed a median survival of 17.6 months in
sixty-eight patients with inoperable liver metastases
being treated with individualized stereotactic body radio-
therapy (SBRT) with a median SBRT dose of 41.8 Gy in
six fractions over two weeks [2]. No RILD or other grade
3 - 5 liver toxicity was seen. Also Rusthoven et al. demon-
strated in a multi-institutional trial with forty-seven
patients (with one to three liver metastases) that high-
dose liver SBRT is safe and effective with a median sur-
vival of 20.5 months with only one patient presenting
with grade 3 toxicity [6]. Localablative irradiation thera-
pies of liver malignancies are of great value especially for
patients who are not suitable for surgical interventions.
In this study we sought to determine threshold doses
for hepatic dysfunction as well as toxic effects e.g. after
repeated irradiation treatments of liver metastases due to
local failure. As a result we found that repeated sessions
of high dose rate, single fraction irradiation at very high
dose levels targeting identical or intersecting liver vol-
umes were safe.
In our trial we did not observe any acute or long term
toxicity despite hepatic dysfunction in areas of high dose
accumulation.
One relevant factor for the tolerance to irradiation is
the critical single dose α/β in Gy, which describes the sen-
sitivity to the dose per fraction and/or dose rate of a par-
ticular tissue, either tumor or organ. The ratio α/β
describes the initial form of the curvature of the underly-
ing cell survival curves [27-29]. Small α/β-ratios are asso-
ciated with a broader shoulder of the dose-response
curve indicating a large dependency of the radiation
effect on the dose per fraction, while large values of α/β
indicate only minor fractionation sensitivity. These indi-
vidual endpoints for specific tissues were first described
in animal studies [30] and have been confirmed by
numerous clinical data [29].
In our study we calculated the D90 of the pseudolesions
for different α/β-values (2, 3, 10, 20 and 100) and did not
find clinically relevant differences. The BED (biologically
Figure 5 Based on the total 3D-Dtot-data set, Amira software cal-
culated dose-volume histograms for all different α/β-values.
Figure 6 Mean D90 for different α/β-values (2, 3, 10, 20, 100) of all 
patients. Statistically there was a significant difference in the D90 re-
sults but the differences for clinical α/β-values were less than 1 Gy and 
therefore of no clinical. The star (*) represents one outlier in the series 
of calculation.Rühl et al. Radiation Oncology 2010, 5:44
http://www.ro-journal.com/content/5/1/44
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equivalent dose) causing injury to 90% of liver paren-
chyma was approximately 23 Gy (table 2). Obviously, the
superposition of dose distributions with large gradients
reduces the dependency on α/β.
Time factors (describing repair kinetics) had no or neg-
ligible influence in our study since the interval between
two applications (between 4 weeks and 14 months, mean
5 months, table 1) was long enough to ensure sufficient
repair [31,32]. We additionally propose that the dose rate
variability as a result of the distance relative to the cathe-
ters had no relevant influence on repair capacity.
However , we observed a trend to a correlation of the
D90 and the time intervals between the interventions as a
result of regeneration or recovery of the irradiated liver
tissue. This is in accordance with 2 previous trials per-
formed by our own group, where the greatest volume of
function loss after single applications of CT-guided HDR
brachytherapy occurred after 6 weeks to 3 months
[13,14]. Six months after irradiation, the volume with
dysfunctional liver tissue had decreased significantly. We
deduced a mean tolerance dose for irreversible damage
above a dose level of 15 Gy (D90) applied as a single radia-
tion dose. At a dose exposure between 10 and 15 Gy,
hepatic dysfunction proved to be reversible [13]. These
results are somewhat contrary to a trial performed by
Lawrence et al. who demonstrated just minor recovery of
liver cell plates after six months and up to 6 years [19].
In our present trial, MRI was acquired between 3 and
31 months (median 10 months) after irradiation and we
expected liver regeneration in the irradiated areas
between 10 - 18 Gy. Nevertheless, we still found a signifi-
cant dependency between the D90 and the time interval
from the first irradiation to the last MRI. In addition, we
found a trend to a correlation of the D90 and the time
intervals between the different irradiation sessions (table
3). Therefore, a long-term regeneration potential proba-
bly exists. With respect to the clinical endpoint liver fail-
ure we wish to add that even after multiple applications of
HDR-brachytherapy in adjacent liver areas the (cumula-
tive) volume of radiation injury did never exceed 803 mL
(mean 336.7 mL). We therefore never reached a treat-
ment volume critical for the overall liver function, i.e. >60
- 70% of the whole liver volume (mean 1669.16 mL).
On the other hand an inverse correlation between the
overexposed (i.e. damaged) volume size and the equiva-
lent tolerance dose (isoeffect-isodose for the impairment
of hepatocyte function) was found. A volume threshold
was found at 200 mL (table 4). For volumes <200 mL the
tolerance dose increased up to 30 Gy. These results are in
line with the previously published dose-volume effect of
hepatic repair [14]. The tolerance dose of D90  (single
dose) as determined in a previous study for a single HDR
application was ~ 15 Gy [13]. A re-calculation of the BED
from 15 Gy (single) for different α/β to conventional frac-
tionation would result in a BED (α/β = 3) of 54 Gy, BED
(α/β = 5) of 42 Gy, or BED (α/β = 10) of 31 Gy. In compar-
ison, the tolerated D90 (2 Gy) of BED ~ 23 Gy in our study
proved to be surprisingly low and suggests in particular
that α/β for liver tissue might be higher than 5 Gy. The
first (and most important) reason for this contradictory
result probably is the small liver volume exposed to a sin-
gle high dose in the referenced trial [13]. Under these cir-
cumstances a higher potential for regeneration might
exist. For larger volumes (>200 mL) and repeated HDR
applications, the tolerance doses were even below the
limits for whole liver irradiation of approximately 30 Gy
Table 3: D90 (for α/β = 2) tested against various variables 
for correlation analysis.
PEARSON CORRELATION D90 (α/β = 2)
Interventions (n) p = 0.004
Cumulative Pseudolesion (cm3) p = 0.037
Interval: first irradiation - MRT 
(months)
p = 0.005
Interval: last irradiation - MRT 
(months)
p = 0.745
Mean interval between several 
interventions (ΣT/n)
p = 0.092
The D90 (for α/β = 2) correlated significantly positive with the 
number of interventions and the interval between the first 
irradiation and the last MRI (p < 0.05). There was a significant 
negative correlation between the D90 (for α/β = 2) and the volume 
of the cumulative pseudolesion (p = 0,037). There was a trend for a 
positive correlation (p = 0.092) between the D90 (for α/β = 2) and 
the mean interval between several interventions (ΣT/n).
Table 4: The comparison between the two groups of 
different cumulative pseudolesion volumes (≤200 mL; 
>200 mL) showed a statistically significant difference in 
the D90 (α/β = 2). 
Critical irradiation volume D90 (α/β = 2)
Cum. Pseudolesion ≤200 mL 
(n = 5)
30.1 Gy
Cum. Pseudolesion >200 mL 
(n = 15)
19.1 Gy
t-test p = 0.01
The statistically significant level was set at p-value ≤ 0.05.Rühl et al. Radiation Oncology 2010, 5:44
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as described in the literature. However it has to be men-
tioned that most of the patients have been treated with
potentially hepatotoxic cytotoxics or new biological
agents before or between the interventions, which may
cause specific toxic effects in the liver and potentially lead
to a reduced tolerance of the liver although most adverse
reactions are idiosyncratic and are due to individual
patient differences in susceptibility to drug-induced liver
injury or inability to recover from the injury. Most
patients tolerate the agent, or can adapt to it [33]. Clini-
cally one-third or even two-thirds of the liver can be inac-
tivated with no symptomatic liver function degradation.
This is not clearly stated in the Emami report in 1991,
which established baseline partial liver tolerances [26].
Dawson et al. further adjusted the Lyman model parame-
ters in 2002 and derived the TD5/5 (in 1.5 Gy BID) for 1/
3 of the liver volume = 107 Gy (~94 Gy in 2 Gy/fx), for 2/
3 = 54 Gy (~48 Gy in 2 Gy/fx). They calculated a 5% risk
of RILD for whole liver radiation therapy (3/3) with 32 Gy
in 2 Gy/fx [7].
In our study the tolerance doses of liver parenchyma
fell in the range of 22 - 24 Gy (conventional fraction-
ation), which is clearly below the data in the literature.
This might be a result of chemotherapy pretreatments in
almost all our patients. However, even a BED of 22 - 24
Gy as determined in this study implies large clinical
potential for irradiation of liver metastases if the hepatic
radiation injury is limited to moderate volumes (table 1).
Furthermore, we did not find clinically relevant late toxic-
ity in any patient undergoing multiple applications of
h i g h - d o s e - r a t e  b r a c h y t h e r a p y .  I n  n o n e  o f  o u r  i m a g i n g
studies fibrotic changes or considerable hypertrophy of
the uninvolved liver was documented. All patients dem-
onstrated normal liver function parameters before and
after CT-guided brachytherapy.
Conclusion
We conclude that repeated high dose rate single fraction
irradiation of intersecting liver volumes is safe. Very high
tumor doses and repeated applications of brachytherapy
and potentially stereotactic irradiation are possible for
liver metastases treatments without an increased risk of
liver failure. In our opinion caution is warranted in whole
liver irradiation applying external techniques.
Our data suggests that the tolerance dose in a pre-
treated liver might not be < 30 Gy using fractions of 2 Gy
as stated in the literature but as low as 22 - 24 Gy.
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